logo1
Resources and Advisory Services
Rethinking the CEO - BoD Chair Thing...

No, we still think the CEO should not serve as BoD Chair. Actually, we think CEOs should not even serve on the BoD. Now, more than before, we think investors should make it a priority.

 

A few months ago, we identified only two-and-a-half priorities for investors: eliminate poison pills, destagger BoDs, and (maybe) achieve proxy access. We dismissed many others, including majority voting, pay disclosure, political contribution disclosure ... and separating the CEO and BoD Chair roles. Recent events in the Allergan situation changed our mind.

 

See a current blog post to find out more.

 

Recent TAI blog posts

You can find other useful resources at the TAI website, including our research on "Effective Activism, on the Cheap", our white paper with the basics on activist investing, and our new guides on exempt solicitationconsent solicitation, and special shareholder meetings. 
For further information, or to discuss a specific turnaround situation, please contact:
 
Michael R. Levin
[email protected]
847.830.1479